(1551688) Expression of SIGLEC-10 ligands CD24 and CD52 limit T cell and CAR-T cell function in CLL

Primary Author(s)

• JV

  Jaco A.C. Van Bruggen, PhD

  Postdoctoral researcher
  Amsterdam University Medical Centers
  Amsterdam, Netherlands

Co-Author; Presenting Author(s)

• FP

  Fleur S. Peters, PhD

  Postdoctoral Researcher
  Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam
  Amsterdam, Netherlands

  Slides

Co-Author(s)

• GC

  Gaspard Cretenet, PhD

  1 Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam institute for Infection and Immunity, Amsterdam, The Netherlands; 2 Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands
  Amsterdam, The Netherlands
• PM

  Perry D. Moerland, PhD

  Amsterdam University Medical Centers
  Amsterdam, Netherlands
• AJ

  Aldo Jongejan, PhD

  Amsterdam University Medical Centers
  Amsterdam, Netherlands
• 

  J. Joseph Melenhorst, PhD

  Vice Chair
  Cleveland Clinic,Center for Immunotherapy & Precision Immuno-Oncology
  Cleveland, OH, United States
• Gv

  Gerritje J.W. van der Windt, PhD

  Amsterdam University Medical Centers
  Amsterdam, Netherlands
• EE

  Eric Eldering, PhD

  1 Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam institute for Infection and Immunity
  Amsterdam, The Netherlands
• 

  Arnon P. Kater, MD, PhD

  Deputy Head, Clinical Hematologist, Head of Research Lab
  Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam
  Amsterdam, Netherlands